ReportGem ReportGem

U.S. COMPANY FILING

NOVO NORDISK A S — Form 6-K filed 2026-08-04

Filed: 2026-08-04Company: NOVO NORDISK A STicker: NVOExchange: NYSEForm: 6-KReport period: 2026-06-30SEC accession: 0000353278-26-000023Event: guidanceMateriality: 82

Filing text preview

Novo Nordisk reported Q2 2026 sales up 3% (CER) and adjusted operating profit up 11%. Wegovy pill surpassed 265,000 weekly US prescriptions; EMA approved Wegovy pill and 7.2mg pen. Ziltivekimab failed phase 3, leading to DKK 6.3bn impairments. Full-year adjusted sales and profit growth guidance raised to 0% to -6% (CER).

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-08-04Super Micro Says Top Management Didn't Know of Diversion Scheme2026-08-20Deoleo Shareholders Review Strategic Alternatives for Olive-Oil Business2026-08-20SSE Issues Regulatory Work Letter to Nanmo Bio2026-08-20Autohome Inc. files Form 6-K2026-08-20Sadot Group Inc. Files 8-K: Material Definitive Agreement and Unregistered Sales of Equity Securities2026-08-20WANG ON GROUP: Major transaction regarding disposal of target company and notice of extraordinary general meeting2026-08-206-K2026-08-04 · 6-K